Clinerion uses patient electronic health records (EHRs) to provide customers with patient data analytics services. The company has received a patent for its technology, which matches anonymized records with corresponding hospital records to identify potential clinical trial participants.
Through its partnership with Provisio, the company’s hospital, clinic and medical practice coverage now encompasses almost 140m patients across four continents.
The partnership is open-ended, Ulf Claesson, CEO of Clinerion told Outsourcing-Pharma.com. "We plan for a long-term productive and mutually beneficial relationship," he added.
Additionally, the partnership adds Provisio’s Outreach Assistance service to Clinerion’s US portfolio. According to the company, the service provides “data-driven intelligence” on the locations of pre-qualified patients.
"By joining forces, Clinerion and Provisio geographically extend each other’s service offering," said Claesson. "This naturally increases the attractiveness of the joint offer by providing more comprehensive services to support international trial sponsors."
International trials are already being extended to the US by jointly delivering services with Provisio, Claesson said.
"We will continue to work closely together on trials with a global scale as sponsors come to each of us," he added.
At the beginning of the year, the company told us its goal was to have 50m patients on board by the end of Q2 2017 and key centers “in most European markets” by the end of the year. In May, Clinerion also expanded its services into countries in Eastern Europe, the Middle East, and Africa (EEMEA).